

VIRGINIA ONCOLOGY ASSOCIATES 12TH ANNUAL EDUCATIONAL CONFERENCE


New Developments in Oncology:

ADDRESSING NOVEL THERAPIES IN ONCOLOGY & HEMATOLOGY

Saturday, October 8, 2011 · 8:00 AM – 2:45 PM

Hilton Virginia Beach Oceanfront · Virginia Beach, VA

JOINTLY SPONSORED BY:

 **Duke University**
School of Medicine

 **Virginia**
Oncology Associates

VIRGINIA ONCOLOGY ASSOCIATES 12TH ANNUAL EDUCATIONAL CONFERENCE WILL BE HELD AT THE HILTON OCEANFRONT HOTEL IN VIRGINIA BEACH, VIRGINIA

ON OCTOBER 8, 2011. This year's didactic program brings together the best regional and national oncology and hematology professionals for clinical discussions on progressive research, scientific experience and therapeutic triumphs.

The audience will include Medical Oncologists, Surgical Oncologists, Pathologists, Pulmonologists, Radiation Oncologists, Internists and Internal Medicine Subspecialists, Thoracic Surgeons, Head and Neck Surgeons, Family Practitioners, General Surgeons, Physician Assistants, Nurse Practitioners and Nurses, among other medical practitioners.

NANCY DAWSON, MD

William M. Scholl Professor of Medicine and Oncology
Georgetown University Hospital
Washington, DC

JOHN V. HEYMACH, MD, PHD

Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

JOHN KELTON, MD, FRCPC

Professor, Department of Medicine
McMaster University
Hamilton & Ontario, Canada

THOMAS O'DORISIO, MD


Professor of Medicine
The University of Iowa Hospital and Clinics
Iowa City, Iowa

MARK PEGRAM, MD

Professor of Medicine
UM Sylvester Comprehensive Cancer Center
Miami, FL

RICHARD RIEDEL, MD

Assistant Professor of Medicine
Duke University Medical Center
Durham, NC




FACULTY

AGENDA

CONFERENCE AGENDA

A brief Question & Answer period will follow each speaker's presentation.

- | | |
|---------------------|-------------------------------------------------------------------------------------------|
| 8:00 AM | BREAKFAST / REGISTRATION |
| 8:10 AM - 8:15 AM | WELCOME / INTRODUCTIONS
Edward R. George, MD, FACP |
| 8:15 AM - 9:00 AM | NEW DEVELOPMENTS IN THE THEORY AND MANAGEMENT OF BREAST CANCER
Mark Pegram, MD |
| 9:05 AM - 9:50 AM | ITP AND HIT: AN UPDATE FOR 2011
John Kelton, MD, FRCPC |
| 9:55 AM - 10:10 AM | BREAK |
| 10:10 AM - 10:55 AM | NEW ADVANCES IN LUNG CANCER MANAGEMENT
John V. Heymach, MD, PhD |
| 11:00 AM - 11:45 AM | THE LATEST DEVELOPMENTS IN NEUROENDOCRINE TUMOR MANAGEMENT
Thomas O'Dorisio, MD |
| 11:50 AM - 12:50 PM | LUNCH |
| 12:50 PM - 1:35 PM | PROSTATE CANCER: NEW BREAKTHROUGHS IN DRUG THERAPIES
Nancy Dawson, MD |
| 1:40 PM - 2:25 PM | NEW DEVELOPMENTS IN THE TREATMENT OF SARCOMAS
Richard Riedel, MD |
| 2:25 PM - 2:45 PM | EVALUATIONS AND WRAP-UP |



LEARNING OBJECTIVES

- Identify current evidence based practice for treatment of breast, lung, and prostate cancer in order to provide optimal care to cancer patients
- Identify current evidence based practice for treatment of ITP and HIT in order to provide optimal care to cancer patients
- Identify current evidence based practice for treatment of neuroendocrine tumors and sarcomas in order to provide optimal care to cancer patients

SPECIAL NEEDS STATEMENT

The Duke Oncology Network is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.

DISCLAIMER The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

RESOLUTION OF CONFLICTS OF INTEREST In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.


COMMERCIAL SUPPORT

ACKNOWLEDGMENT This CME activity is supported by educational grants from Bayer Healthcare Pharmaceuticals. A complete list of sponsors will be published in the course syllabus.

ACCREDITATION This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Duke University School of Medicine and Virginia Oncology Associates. The Duke University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION The Duke University School of Medicine designates this educational activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE The Duke University School of Medicine adheres to ACCME essential areas, standards, and policies regarding industry support of continuing medical education. Disclosure of faculty and commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off label, experimental, or investigational uses of drugs or devices in their presentations.



FOR 12 YEARS, NEW DEVELOPMENTS IN ONCOLOGY HAS OFFERED A COMPREHENSIVE VIEW OF ADVANCEMENTS IN TREATMENTS, TECHNIQUES AND TECHNOLOGIES FOR TREATING AND MANAGING CANCER AND BLOOD DISEASES, AS WELL AS RELATED SYMPTOMS.

NEW DEVELOPMENTS IN ONCOLOGY

HILTON VIRGINIA BEACH OCEANFRONT
VIRGINIA BEACH, VIRGINIA

SATURDAY, OCTOBER 8, 2011

This event is presented by Duke Oncology Network and is jointly sponsored by Virginia Oncology Associates and Duke School of Medicine

